Serina Therapeutics Announces Completion of Cohort 1 Enrollment, Dosing in SER-252 Parkinson’s Trial

Serina Therapeutics Inc

Serina Therapeutics Inc

SER

0.00
  • Serina Therapeutics disclosed completion of Cohort 1 enrollment and dosing in its Phase 1b registrational trial of SER-252.
  • Eight advanced Parkinson’s patients dosed across US and Australian sites, ahead of prior guidance for end-Q3 2026 completion.
  • An independent Safety Monitoring Committee will review blinded Cohort 1 safety and tolerability to guide the next dose-escalation step.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Serina Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607230600PRIMZONEFULLFEED9766948) on July 23, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.